Details

Autor(en) / Beteiligte

• Vercauteren, Jurgen
• Derdelinckx, Inge
• Sasse, André
• Bogaert, Marleen
• Ceunen, Helga
• De Roo, Ann
• De Wit, Stephane
• Deforche, Koen
• Echahidi, Fedoua
• Fransen, Katrien
• Goffard, Jean-Christophe
• Goubau, Patrick
• Goudeseune, Elodie
• Yombi, Jean-Cyr
• Lacor, Patrick
• Liesnard, Corinne
• Moutschen, Michel
• Pierard, Denis
• Rens, Roeland
• Schrooten, Yoeri
• Vaira, Dolores
• van den Heuvel, Annelies
• van der Gucht, Bea
• van Ranst, Marc
• van Wijngaerden, Eric
• Vandercam, Bernard
• Vekemans, Marc
• Verhofstede, Chris
• Clumeck, Nathan
• Vandamme, Anne-Mieke
• van Laethem, Kristel

Titel

Prevalence and epidemiology of HIV type 1 drug resistance among newly diagnosed therapy-naive patients in Belgium from 2003 to 2006

Ist Teil von

• AIDS research and human retroviruses, 2008-03, Vol.24 (3), p.355

Ort / Verlag

United States

Erscheinungsjahr

2008

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• This study is the first prospective study to assess the prevalence, epidemiology, and risk factors of HIV-1 drug resistance in newly diagnosed HIV-infected patients in Belgium. In January 2003 it was initiated as part of the pan-European SPREAD program, and continued thereafter for four inclusion rounds until December 2006. Epidemiological, clinical, and behavioral data were collected using a standardized questionnaire and genotypic resistance testing was done on a sample taken within 6 months of diagnosis. Two hundred and eighty-five patients were included. The overall prevalence of transmitted HIV-1 drug resistance in Belgium was 9.5% (27/285, 95% CI: 6.6-13.4). Being infected in Belgium, which largely coincided with harboring a subtype B virus, was found to be significantly associated with transmission of drug resistance. The relatively high rate of baseline resistance might jeopardize the success of first line treatment as more than 1 out of 10 (30/285, 10.5%) viruses did not score as fully susceptible to one of the recommended first-line regimens, i.e., zidovudine, lamivudine, and efavirenz. Our results support the implementation of genotypic resistance testing as a standard of care in all treatment-naive patients in Belgium.